Compare ANIP & DRH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANIP | DRH |
|---|---|---|
| Founded | 2001 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | N/A | 2005 |
| Metric | ANIP | DRH |
|---|---|---|
| Price | $79.59 | $8.99 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 8 |
| Target Price | ★ $105.83 | $9.41 |
| AVG Volume (30 Days) | 409.7K | ★ 2.4M |
| Earning Date | 11-07-2025 | 02-26-2026 |
| Dividend Yield | N/A | ★ 3.47% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.67 | 0.26 |
| Revenue | $826,880,000.00 | ★ $1,125,008,000.00 |
| Revenue This Year | $44.06 | N/A |
| Revenue Next Year | $9.06 | $17.33 |
| P/E Ratio | $46.26 | ★ $35.77 |
| Revenue Growth | ★ 48.87 | 0.95 |
| 52 Week Low | $52.74 | $6.19 |
| 52 Week High | $99.50 | $9.42 |
| Indicator | ANIP | DRH |
|---|---|---|
| Relative Strength Index (RSI) | 42.91 | 48.62 |
| Support Level | $76.69 | $8.90 |
| Resistance Level | $80.29 | $9.20 |
| Average True Range (ATR) | 2.41 | 0.17 |
| MACD | -0.10 | -0.04 |
| Stochastic Oscillator | 37.74 | 21.36 |
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.
Diamondrock Hospitality Company is a real estate investment trust that owns lodging properties. Its business is to acquire, own, manage, and renovate full-service hotel properties in the United States. It operates in cities such as Chicago, Boston, New York, Denver, and others. Within DiamondRock's holdings, the majority of the hotel brands include Marriott, Starwood, and Hilton. The revenue is divided between room, food and beverage, and others. The room segment contributes the majority of the revenue. The firm's customers include leisure transients, business transients, and group customers.